Vectura Group plc has signed an agreement with Hikma Pharmaceuticals PLC for the global development and commercialization of generic versions of GSK’s Ellipta portfolio, using Vectura’s Open-Inhale-Close dry powder inhaler device.   Following interactions with FDA, the Open-Inhale-Close dry powder inhaler device has the potential to be developed as an AB-rated substitutable drug-device combination for generic versions of the GSK Ellipta portfolio, which had sales of in the U.S. projected to be...